Addressing the Regulatory Hurdles Facing Antibiotic Innovation

Addressing the Regulatory Hurdles Facing Antibiotic Innovation

Although the threat of antibiotic resistance is growing, it can be challenging to get regulatory approval for antibiotics that treat highly resistant bacterial infections. Only a small number of patients contracting such infections meet the requirements to participate in traditional large clinical trials. As a result, researchers have difficulty identifying patients and enrolling them in clinical trials to study treatments for some of the most serious bacterial infections.

To address some of these challenges, and to help patients who have few or no treatment options to battle infections, senior leaders at the U.S. Food and Drug Administration and policymakers on Capitol Hill have discussed the potential for a new, limited-population antibacterial drug (LPAD) pathway. Antibiotics approved under this pathway would be studied for use in smaller, more targeted populations than are antibiotics used for broader indications or conditions. This process could help lower development costs and make clinical trials more feasible for drug companies.

The Antibiotic Development to Advance Patient Treatment (ADAPT) Act, legislation that was originally introduced in 2013, was included as part of the 21st Century Cures Act, a wide-ranging health care bill approved by the House Energy and Commerce Committee on May 21, 2015. A similar Senate measure, the Promise for Antibiotics and Therapeutics for Health (PATH) Act, was introduced by Senators Orrin Hatch (R-UT) and Michael Bennet (D-CO) in January 2015. Both bills would create an LPAD pathway and encourage the development of antibiotics for patients with serious or life-threatening bacterial infections. 


1x1placeholder

Core Principles for a Limited Population Antibacterial Drug Pathway

New pathway will encourage the development of antibiotics and get them to patients faster
Quick View

Core Principles for a Limited Population Antibacterial Drug Pathway

New pathway will encourage the development of antibiotics and get them to patients faster

Additional Resources

The front facade of the Supreme Court of the United States in Washington, DC.
ian-hutchinson-U8WfiRpsQ7Y-unsplash.jpg_master

Agenda for America

Resources for federal, state, and local decision-makers

Quick View

Data-driven policymaking is not just a tool for finding new solutions for emerging challenges, it makes government more effective and better able to serve the public interest.

Lightbulbs
Lightbulbs

States of Innovation

Data-driven state policy innovations across America

Quick View

Data-driven policymaking is not just a tool for finding new solutions for difficult challenges. When states serve their traditional role as laboratories of innovation, they increase the American people’s confidence that the government they choose—no matter the size—can be effective, responsive, and in the public interest.

Antibiotics in Development
19x9 placeholder

Tracking the Pipeline

Identifying each drug, its manufacturer, its potential targets, and where it is in the development process.

Read More
Quick View

Tracking the Pipeline

Identifying each drug, its manufacturer, its potential targets, and where it is in the development process.

Read More